# Intelligent Bio Solutions Inc.: financial statements, quarterly

INBS · Nasdaq · CIK 1725430 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/inbs.md) · [Financials](/companies/inbs/financials.md) · [Filings](/companies/inbs/filings.md) · [Insiders](/companies/inbs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/inbs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [796](/filings/0001493152-24-043927.md) | [764](/filings/0001493152-25-006262.md) | [824](/filings/0001641172-25-009846.md) | [728 d](/filings/0001641172-25-024279.md) | [872](/filings/0001493152-25-021751.md) | [607](/filings/0001493152-26-006311.md) | [729](/filings/0001493152-26-022617.md) | [844 d](/filings/0001493152-26-039136.md) | [1,112](/filings/0001493152-25-021751.md) | [897](/filings/0001493152-26-006311.md) | [1,061](/filings/0001493152-26-022617.md) | [1,146 d](/filings/0001493152-26-039136.md) |
| Cost of revenue | $k | [564](/filings/0001493152-24-043927.md) | [565](/filings/0001493152-25-006262.md) | [645](/filings/0001641172-25-009846.md) | [(87.7) d](/filings/0001641172-25-024279.md) | [525](/filings/0001493152-25-021751.md) | [384](/filings/0001493152-26-006311.md) | [387](/filings/0001493152-26-022617.md) | [508 d](/filings/0001493152-26-039136.md) | [594](/filings/0001493152-25-021751.md) | [437](/filings/0001493152-26-006311.md) | [525](/filings/0001493152-26-022617.md) | [609 d](/filings/0001493152-26-039136.md) |
| Gross profit | $k | [232](/filings/0001493152-24-043927.md) | [199](/filings/0001493152-25-006262.md) | [178](/filings/0001641172-25-009846.md) | [816 d](/filings/0001641172-25-024279.md) | [347](/filings/0001493152-25-021751.md) | [223](/filings/0001493152-26-006311.md) | [341](/filings/0001493152-26-022617.md) | [336 d](/filings/0001493152-26-039136.md) | [518](/filings/0001493152-25-021751.md) | [460](/filings/0001493152-26-006311.md) | [535](/filings/0001493152-26-022617.md) | [537 d](/filings/0001493152-26-039136.md) |
| Research and development | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $k | not reported | [1,705](/filings/0001493152-24-005569.md) | not reported | not reported | not reported | [1,809](/filings/0001493152-26-006311.md) | [2,415](/filings/0001493152-26-022617.md) | [2,723 d](/filings/0001493152-26-039136.md) | not reported | [2,337](/filings/0001493152-26-006311.md) | [2,459](/filings/0001493152-26-022617.md) | [2,990 d](/filings/0001493152-26-039136.md) |
| Operating income | $k | [(2,526)](/filings/0001493152-24-043927.md) | [(1,991)](/filings/0001493152-25-006262.md) | [(2,954)](/filings/0001641172-25-009846.md) | [(2,812) d](/filings/0001641172-25-024279.md) | [(2,725)](/filings/0001493152-25-021751.md) | [(2,264)](/filings/0001493152-26-006311.md) | [(2,560)](/filings/0001493152-26-022617.md) | [(3,106) d](/filings/0001493152-26-039136.md) | [(3,000)](/filings/0001493152-25-021751.md) | [(2,636)](/filings/0001493152-26-006311.md) | [(2,947)](/filings/0001493152-26-022617.md) | [(3,969) d](/filings/0001493152-26-039136.md) |
| Interest expense | $k | [37.4](/filings/0001493152-24-043927.md) | [32.5](/filings/0001493152-25-006262.md) | [42.7](/filings/0001641172-25-009846.md) | [54.6 d](/filings/0001641172-25-024279.md) | [22.3](/filings/0001493152-25-021751.md) | [13.5](/filings/0001493152-26-006311.md) | [7.9](/filings/0001493152-26-022617.md) | [5.3 d](/filings/0001493152-26-039136.md) | [3.9](/filings/0001493152-25-021751.md) | [56.2](/filings/0001493152-26-006311.md) | [4.2](/filings/0001493152-26-022617.md) | [3.3 d](/filings/0001493152-26-039136.md) |
| Net income | $k | [(2,425)](/filings/0001493152-24-043927.md) | [(1,970)](/filings/0001493152-25-006262.md) | [(2,978)](/filings/0001641172-25-009846.md) | [(2,784) d](/filings/0001641172-25-024279.md) | [(2,686)](/filings/0001493152-25-021751.md) | [(2,249)](/filings/0001493152-26-006311.md) | [(2,544)](/filings/0001493152-26-022617.md) | [(3,090) d](/filings/0001493152-26-039136.md) | [(2,983)](/filings/0001493152-25-021751.md) | [(2,678)](/filings/0001493152-26-006311.md) | [(2,863)](/filings/0001493152-26-022617.md) | [(3,908) d](/filings/0001493152-26-039136.md) |
| Diluted EPS | $ per share | [(12.48)](/filings/0001493152-24-043927.md) | [(2.07)](/filings/0001493152-25-006262.md) | [(1.43)](/filings/0001641172-25-009846.md) | not reported | [(0.70)](/filings/0001493152-25-021751.md) | [(4.96)](/filings/0001493152-26-006311.md) | [(4.41)](/filings/0001493152-26-022617.md) | not reported | [(0.35)](/filings/0001493152-25-021751.md) | [(2.82)](/filings/0001493152-26-006311.md) | [(1.80)](/filings/0001493152-26-022617.md) | not reported |
| Basic EPS | $ per share | [(12.48)](/filings/0001493152-24-043927.md) | [(2.07)](/filings/0001493152-25-006262.md) | [(1.43)](/filings/0001641172-25-009846.md) | not reported | [(0.70)](/filings/0001493152-25-021751.md) | [(4.96)](/filings/0001493152-26-006311.md) | [(4.41)](/filings/0001493152-26-022617.md) | not reported | [(0.35)](/filings/0001493152-25-021751.md) | [(2.82)](/filings/0001493152-26-006311.md) | [(1.80)](/filings/0001493152-26-022617.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | period not labelled (2024-04-16) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.1](/filings/0001493152-24-005569.md) | [9.4](/filings/0001493152-24-018167.md) | not reported | [6.3](/filings/0001641172-25-024279.md) | [4.0](/filings/0001493152-24-043927.md) | [2.2](/filings/0001493152-25-006262.md) | [2.8](/filings/0001641172-25-009846.md) | [1.0](/filings/0001493152-26-039136.md) | [1.7](/filings/0001493152-25-021751.md) | [0.7](/filings/0001493152-26-006311.md) | [6.9](/filings/0001493152-26-022617.md) | [4.0](/filings/0001493152-26-039136.md) |
| Current assets | $m | [2.9](/filings/0001493152-24-005569.md) | [11.5](/filings/0001493152-24-018167.md) | not reported | [8.5](/filings/0001641172-25-024279.md) | [6.5](/filings/0001493152-24-043927.md) | [4.1](/filings/0001493152-25-006262.md) | [5.1](/filings/0001641172-25-009846.md) | [4.1](/filings/0001493152-26-039136.md) | [4.5](/filings/0001493152-25-021751.md) | [12.2](/filings/0001493152-26-006311.md) | [9.7](/filings/0001493152-26-022617.md) | [7.1](/filings/0001493152-26-039136.md) |
| Total assets | $m | [8.8](/filings/0001493152-24-005569.md) | [17.0](/filings/0001493152-24-018167.md) | not reported | [13.8](/filings/0001641172-25-024279.md) | [11.7](/filings/0001493152-24-043927.md) | [8.7](/filings/0001493152-25-006262.md) | [9.6](/filings/0001641172-25-009846.md) | [8.2](/filings/0001493152-26-039136.md) | [10.0](/filings/0001493152-25-021751.md) | [17.7](/filings/0001493152-26-006311.md) | [14.9](/filings/0001493152-26-022617.md) | [11.9](/filings/0001493152-26-039136.md) |
| Current liabilities | $m | [5.2](/filings/0001493152-24-005569.md) | [5.7](/filings/0001493152-24-018167.md) | not reported | [5.5](/filings/0001641172-25-024279.md) | [5.7](/filings/0001493152-24-043927.md) | [4.4](/filings/0001493152-25-006262.md) | [4.6](/filings/0001641172-25-009846.md) | [5.4](/filings/0001493152-26-039136.md) | [5.1](/filings/0001493152-25-021751.md) | [5.1](/filings/0001493152-26-006311.md) | [4.6](/filings/0001493152-26-022617.md) | [4.9](/filings/0001493152-26-039136.md) |
| Total liabilities | $m | [5.7](/filings/0001493152-24-005569.md) | [6.0](/filings/0001493152-24-018167.md) | not reported | [5.6](/filings/0001641172-25-024279.md) | [5.8](/filings/0001493152-24-043927.md) | [4.5](/filings/0001493152-25-006262.md) | [4.6](/filings/0001641172-25-009846.md) | [5.4](/filings/0001493152-26-039136.md) | [6.6](/filings/0001493152-25-021751.md) | [6.8](/filings/0001493152-26-006311.md) | [6.1](/filings/0001493152-26-022617.md) | [6.7](/filings/0001493152-26-039136.md) |
| Long-term debt | $m | not reported | not reported | [1.7](/filings/0001493152-26-039136.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [3.3](/filings/0001493152-24-005569.md) | [11.1](/filings/0001493152-24-018167.md) | not reported | [8.3](/filings/0001641172-25-024279.md) | [6.1](/filings/0001493152-24-043927.md) | [4.4](/filings/0001493152-25-006262.md) | [5.1](/filings/0001641172-25-009846.md) | [3.0](/filings/0001493152-26-039136.md) | [3.6](/filings/0001493152-25-021751.md) | [11.1](/filings/0001493152-26-006311.md) | [9.0](/filings/0001493152-26-022617.md) | [5.5](/filings/0001493152-26-039136.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,312)](/filings/0001493152-24-043927.md) | [(2,869) d](/filings/0001493152-25-006262.md) | [(2,447) d](/filings/0001641172-25-009846.md) | [(2,944) d](/filings/0001641172-25-024279.md) | [(2,387)](/filings/0001493152-25-021751.md) | [(2,325) d](/filings/0001493152-26-006311.md) | [(2,755) d](/filings/0001493152-26-022617.md) | [(2,210) d](/filings/0001493152-26-039136.md) | [(2,847)](/filings/0001493152-25-021751.md) | [(1,568) d](/filings/0001493152-26-006311.md) | [(4,331) d](/filings/0001493152-26-022617.md) | [(3,182) d](/filings/0001493152-26-039136.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [70.4](/filings/0001493152-25-021751.md) | [68.2 d](/filings/0001493152-26-006311.md) | [(12.9) d](/filings/0001493152-26-022617.md) | [0.0 d](/filings/0001493152-26-039136.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [744](/filings/0001493152-23-039898.md) | [75.7](/filings/0001493152-24-005569.md) | [92.4](/filings/0001493152-24-018167.md) | [194](/filings/0001493152-24-043927.md) | [950](/filings/0001493152-25-006262.md) | [2,080](/filings/0001641172-25-009846.md) | [3,811](/filings/0001493152-25-021751.md) | [454](/filings/0001493152-26-006311.md) | [577](/filings/0001493152-26-022617.md) | [8,547](/filings/0001493152-25-021751.md) | [951](/filings/0001493152-26-006311.md) | [1,594](/filings/0001493152-26-022617.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,027,470 at 2026-08-18, from the cover of the [10-K/A filed 2026-10-21](/filings/0001493152-26-047925.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.